Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001764013-26-000046
Filing Date
2026-04-09
Accepted
2026-04-09 16:25:16
Documents
1
Period of Report
2026-04-07

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1775766313.html 4  
1 FORM 4 wk-form4_1775766313.xml 4 6646
  Complete submission text file 0001764013-26-000046.txt   8187
Mailing Address C/O AXOVANT SCIENCES, INC. 1441 BROADWAY, 3RD FLOOR NEW YORK NY 10018
Business Address
Pande Atul (Reporting) CIK: 0001643071 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38906 | Film No.: 26851943

Mailing Address 1000 PARK FORTY PLAZA DURHAM NC 27713
Business Address 1000 PARK FORTY PLAZA DURHAM NC 27713 917-410-3120
Immunovant, Inc. (Issuer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)